Testimonial - Candice-Marie Interview with NORI Thriver

     This case report documents the medical history of a cancer patient that contacted NORI in May 2012. This patient had undergone complete thyroidectomy and lymph node dissection.  The cancer returned in additional lymph nodes in the chest and lungs. Thyrogobulin level was 13 and the standard treatment options were more surgeries and radioactive iodine therapy. The patient decided to try a natural approach and began the NORI protocol which at that time consisted of a mostly fruit diet and high dose sodium selenite. Thyroglobulin dropped  within 3 months to a nearly undetectable level. This patient had maintained this very low tumor marker level for over 4 years until there was a slight rise. Reinitiating the NORI program lowered it again to a near undetectable level.  This patient as of October 2019 is in complete remission.

     This patient contacted NORI in April 2018 and was suffering from extreme bone pain from breast cancer metastasis to the spine and other skeletal structures.  CA15-3 tumor marker was nearly 1000 and scans clearly showed multiple lesions mainly in the bones. The NORI protocol was immediately initiated which consisted of cycled methionine restriction and two nutraceutical combinations. One combination consists of sodium selenite, vitamin K3, genipin (gardenia fruit extract. The second combination is grapeseed/pine bark extract, lutein, green tea extract and eurycoma longifolia extract. CBD was also included and boswellia serrata with ginger extract was added more recently. Bone pain subsided within the first three months and CA15-3 dropped to 250.  The only conventional treatment incorporated was an aromatase inhibitor.  As of October 2019, this patient enjoys a high quality of life while continuing on the NORI program. Spot radiation has been applied recently to a lesion that has been causing some discomfort. Tumor markers remain stable and manageable.

     This patient contacted NORI in December 2018 and was challenged with advanced CLL with a lymphocyte count of 360,000. The NORI protocol was started January 2019 and the lymphocyte count continues to drop and is now at about 50% of the peak value of 360,000. The diet was not low-methionine initially due to weight concerns but is now a cycled low-methionine diet and weight is being maintained. The primary nutraceuticals are high dose sodium selenite both orally and IV,  genipin (gardenia fruit extract) boswellia serrata/ginger extract, high dose DHA (algae oil derived omega-3) and CBD. Ozone therapy is being administered in a small portable infrared steam sauna. No conventional treatments have been administered. Expectations are that this patient will continue to experience decline in lymphocyte count and improvements in red blood cell count and other hematological parameters. It is important to mention that this patient is an integrative medical doctor and had tried to self-treat for 8 years without any success. We are very hopeful that the NORI program will drive the CLL into complete remission.

     This case involves a patient that was diagnosed with Non-Hodgkin's Lymphoma (NHL) in May 2018.  No conventional treatments were administered since the diagnosis. This patient began the NORI protocol  September 2018. As of October 2019, there has been no progression of the enlarged lymph node on the neck and no signs of any other lymph node involvement. It is believed that the original lymph node is now benign. All blood markers are well within normal range. This patient was advised by the oncologist to keep doing what you are doing. The protocol followed by this patient was a cycled methionine restricted diet, high dose sodium selenite, berberine, genipin (gardenia fruit extract and CBD (low-dose). The patient is feeling great with lots of energy and stable healthy weight. Sodium selenite was the most likely the primary element of the protocol that generated the response because published human clinical trials demonstrate the effectiveness of sodium selenite for treating NHL.

     This  patient contacted NORI in May 2018 and began the protocol in June 2018. The patient's previous treatments were total thyroidectomy and radioactive iodine. There was a recurrence of thyroid cancer with a tumor marker at 8.0 (Thyroglobulin) upon beginning the NORI protocol. The tumor marker was rising rapidly. No conventional treatments were administered. The nutraceuticals administered are high dose sodium selenite, genipin, berberine and vitamin K3. A cycled methionine restricted is being followed. Thyroglobulin dropped to 5.9 after two months on the protocol. Since that time, the tumor marker has been essentially stable for 1 year. Further reduction in the tumor marker is expected after modifications to the nutraceutical schedule. This patient is enjoying excellent health.

     This a recent case (2020) involving a stage IV papillary thyroid cancer patient that had complete thyroidectomy and the cancer recurred. At the time of initiation of the NORI protocol, the thyroglobulin tumor marker was 6.0 and dropped to only 0.25 after only 2 months. This rapid response was from the NORI protocol only. The patient strictly followed a methionine restricted diet and the primary nutraceuticals were sodium selenite and vitamin E delta tocotrienol. Thyroid cancer continues to show excellent responses to the NORI protocol. The reason for these rapid responses is likely due to the slow progressing nature of thyroid cancer. It is noted that conventional treatments for thyroid cancer are largely ineffective. The conventional approach typically involves multiple surgeries and radioactive iodine therapy. There are no effective chemotherapeutic agents.

     November 2019 a 53 year old stage IV prostate cancer patient contacted NORI and had a PSA of 395.  NORI advised hormonal therapy with Lupron and the NORI protocol. In 1 month, PSA dropped to 30 and a month later dropped to well within the normal range (PSA = 1.7, normal is less than 4.0). This patient had no surgery, chemotherapy or radiation and as of September 2020, MRI is clear of any metastatic lesions and a normal prostate. The patient will continue to follow the NORI protocol along with intermittent Lupron treatment. Lupron depletes testosterone and can be effective in treating prostate cancer but is typically not as effective as demonstrated in this case. This patient followed a 7 day on and 7 day off methionine restricted diet plan and nutraceuticals including sodium selenite, vitamin K3 and Vitamin E delta tocotrienol.